Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients
Diabetic nephropathy (DN) is the main reason for end-stage renal disease. Microalbuminuria as the non-invasive available diagnosis marker lacks specificity and gives high false positive rates. To identify and validate biomarkers for DN, we used in the present study urine samples from four patient gr...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/3/639 |
id |
doaj-c17fa500a0e64e1e8d81a9df471ac899 |
---|---|
record_format |
Article |
spelling |
doaj-c17fa500a0e64e1e8d81a9df471ac8992020-11-25T02:16:10ZengMDPI AGJournal of Clinical Medicine2077-03832020-02-019363910.3390/jcm9030639jcm9030639Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic PatientsMichael Koziolek0Gerhard A. Mueller1Gry H. Dihazi2Klaus Jung3Constanze Altubar4Manuel Wallbach5Ivana Markovic6Dirk Raddatz7Olaf Jahn8Hülya Karaköse9Christof Lenz10Henning Urlaub11Abdelhi Dihazi12Abdellatif El Meziane13Hassan Dihazi14Clinic for Nephrology and Rheumatology, University Medical Center Göttingen 1, 37075 Göttingen, GermanyClinic for Nephrology and Rheumatology, University Medical Center Göttingen 1, 37075 Göttingen, GermanyInstitute for Clinical Chemistry/UMG-Laboratories, University Medical Center Göttingen, 37075 Göttingen, GermanyInstitute for Animal Breeding and Genetics, University of Veterinary Medicine Hannover, 30559 Hannover, GermanyClinic for Nephrology and Rheumatology, University Medical Center Göttingen 1, 37075 Göttingen, GermanyClinic for Nephrology and Rheumatology, University Medical Center Göttingen 1, 37075 Göttingen, GermanyInstitute for Clinical Chemistry/UMG-Laboratories, University Medical Center Göttingen, 37075 Göttingen, GermanyClinic for Gastroenterology and Gastrointestinal Oncology, University Medical Center Göttingen, 37075 Göttingen, GermanyProteomics Group, Max-Planck-Institute of Experimental Medicine, 37075 Göttingen, GermanyClinic for Nephrology and Rheumatology, University Medical Center Göttingen 1, 37075 Göttingen, GermanyInstitute for Clinical Chemistry/UMG-Laboratories, University Medical Center Göttingen, 37075 Göttingen, GermanyInstitute for Clinical Chemistry/UMG-Laboratories, University Medical Center Göttingen, 37075 Göttingen, GermanyLaboratory of Biotechnology and Molecular Bioengineering, Faculty of Sciences and Techniques Gueliz, Cadi Ayyad University, Marrakech 40000, MoroccoLaboratory of Biotechnology and Molecular Bioengineering, Faculty of Sciences and Techniques Gueliz, Cadi Ayyad University, Marrakech 40000, MoroccoClinic for Nephrology and Rheumatology, University Medical Center Göttingen 1, 37075 Göttingen, GermanyDiabetic nephropathy (DN) is the main reason for end-stage renal disease. Microalbuminuria as the non-invasive available diagnosis marker lacks specificity and gives high false positive rates. To identify and validate biomarkers for DN, we used in the present study urine samples from four patient groups: diabetes without nephropathy, diabetes with microalbuminuria, diabetes with macroalbuminuria and proteinuria without diabetes. For the longitudinal validation, we recruited 563 diabetic patients and collected 1363 urine samples with the clinical data during a follow-up of 6 years. Comparative urinary proteomics identified four proteins Apolipoprotein A-I (APOA1), Beta-2-microglobulin (B2M), E-cadherin (CDH1) and Lithostathine-1-alpha (REG1A), which differentiated with high statistical strength (<i>p</i> < 0.05) between DN patients and the other groups. Label-free mass spectrometric quantification of the candidates confirmed the discriminatory value of E-cadherin and Lithostathine-1-alpha (<i>p</i> < 0.05). Immunological validation highlighted E-cadherin as the only marker able to differentiate significantly between the different DN stages with an area under the curve (AUC) of 0.85 (95%-CI: [0.72, 0.97]). The analysis of the samples from the longitudinal study confirmed the prognostic value of E-cadherin, the critical increase in urinary E-cadherin level was measured 20 ± 12.5 months before the onset of microalbuminuria and correlated significantly (<i>p</i> < 0.05) with the glomerular filtration rate measured by estimated glomerular filtration rate (eGFR).https://www.mdpi.com/2077-0383/9/3/639diabetic nephropathyearly diagnosis/prognosise-cadherinearly biomarker |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michael Koziolek Gerhard A. Mueller Gry H. Dihazi Klaus Jung Constanze Altubar Manuel Wallbach Ivana Markovic Dirk Raddatz Olaf Jahn Hülya Karaköse Christof Lenz Henning Urlaub Abdelhi Dihazi Abdellatif El Meziane Hassan Dihazi |
spellingShingle |
Michael Koziolek Gerhard A. Mueller Gry H. Dihazi Klaus Jung Constanze Altubar Manuel Wallbach Ivana Markovic Dirk Raddatz Olaf Jahn Hülya Karaköse Christof Lenz Henning Urlaub Abdelhi Dihazi Abdellatif El Meziane Hassan Dihazi Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients Journal of Clinical Medicine diabetic nephropathy early diagnosis/prognosis e-cadherin early biomarker |
author_facet |
Michael Koziolek Gerhard A. Mueller Gry H. Dihazi Klaus Jung Constanze Altubar Manuel Wallbach Ivana Markovic Dirk Raddatz Olaf Jahn Hülya Karaköse Christof Lenz Henning Urlaub Abdelhi Dihazi Abdellatif El Meziane Hassan Dihazi |
author_sort |
Michael Koziolek |
title |
Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients |
title_short |
Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients |
title_full |
Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients |
title_fullStr |
Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients |
title_full_unstemmed |
Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients |
title_sort |
urine e-cadherin: a marker for early detection of kidney injury in diabetic patients |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2020-02-01 |
description |
Diabetic nephropathy (DN) is the main reason for end-stage renal disease. Microalbuminuria as the non-invasive available diagnosis marker lacks specificity and gives high false positive rates. To identify and validate biomarkers for DN, we used in the present study urine samples from four patient groups: diabetes without nephropathy, diabetes with microalbuminuria, diabetes with macroalbuminuria and proteinuria without diabetes. For the longitudinal validation, we recruited 563 diabetic patients and collected 1363 urine samples with the clinical data during a follow-up of 6 years. Comparative urinary proteomics identified four proteins Apolipoprotein A-I (APOA1), Beta-2-microglobulin (B2M), E-cadherin (CDH1) and Lithostathine-1-alpha (REG1A), which differentiated with high statistical strength (<i>p</i> < 0.05) between DN patients and the other groups. Label-free mass spectrometric quantification of the candidates confirmed the discriminatory value of E-cadherin and Lithostathine-1-alpha (<i>p</i> < 0.05). Immunological validation highlighted E-cadherin as the only marker able to differentiate significantly between the different DN stages with an area under the curve (AUC) of 0.85 (95%-CI: [0.72, 0.97]). The analysis of the samples from the longitudinal study confirmed the prognostic value of E-cadherin, the critical increase in urinary E-cadherin level was measured 20 ± 12.5 months before the onset of microalbuminuria and correlated significantly (<i>p</i> < 0.05) with the glomerular filtration rate measured by estimated glomerular filtration rate (eGFR). |
topic |
diabetic nephropathy early diagnosis/prognosis e-cadherin early biomarker |
url |
https://www.mdpi.com/2077-0383/9/3/639 |
work_keys_str_mv |
AT michaelkoziolek urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients AT gerhardamueller urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients AT gryhdihazi urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients AT klausjung urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients AT constanzealtubar urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients AT manuelwallbach urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients AT ivanamarkovic urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients AT dirkraddatz urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients AT olafjahn urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients AT hulyakarakose urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients AT christoflenz urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients AT henningurlaub urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients AT abdelhidihazi urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients AT abdellatifelmeziane urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients AT hassandihazi urineecadherinamarkerforearlydetectionofkidneyinjuryindiabeticpatients |
_version_ |
1724892240258531328 |